MEETINGS - ENDO 2001 (US) May 2001:
This article was originally published in Clinica
ENDO 2001, the endocrine society's 83rd annual meeting will be held at the Colorado convention center, Denver, Colorado, on May 20-23. For more information contact the Endocrine Society in the US. Tel: +1 301 941 0200. Fax: +1 301 941 0259. Email: email@example.com www.endo-society.org
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.